(By Oil & Gas 360) – The oil market has spent the past several weeks trading optimism. Prices have retreated from their crisis highs as investors bet that diplomacy, ceasefire extensions, and negotiations between Washington and Tehran will eventually restore flows through the Strait of Hormuz.
Yet a growing number of traders, ****** ysts, and industry executives are warning that markets may be focusing too heavily on headlines while underestimating the physical realities developing underneath.
That concern was reinforced this week when Tom Baker, managing director for Bahrain at global commodities trader Vitol, warned that oil markets may be underpricing the risks ****** ociated with the ongoing Iran conflict. According to Baker, the real challenge may not be crude production itself, but the growing shortage of refined products and the inability of the physical system to recover quickly enough if disruptions continue.
His warning comes as evidence continues to mount that the global energy system is becoming increasingly strained. Iran’s effective restrictions on Hormuz traffic, infrastructure damage across the region, and interruptions to refining and export facilities have already removed substantial volumes from the market.
Vitol estimates that roughly 14 million barrels per day of Middle Eastern supply have been impacted, creating what some market participants describe as the largest supply disruption in modern oil market history.

We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is one of the most undervalued pharma stocks.
TheFly reported on May 11 that Piper Sandler reduced its price target on AMPH from $25 to $21 while maintaining a Neutral stance on the stock following the company’s quarterly results. The firm noted that AMPH has several complex generic products and branded opportunities in its pipeline, but there is limited clarity on when these programs will begin to generate meaningful results. This lack of visibility into the timing of potential pipeline catalysts contributed to the revised outlook.
Earlier on May 7, Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) released its financial results for the first quarter ended March 31, 2026. The company posted net revenues of $171.2 million for the period. Reported GAAP net income came in at $6.4 million, translating to earnings of $0.14 per share. On an adjusted non-GAAP basis, net income was $19.5 million, or $0.42 per share.
The results reflect performance across its portfolio of technically complex generic and proprietary injectable, inhalation, and intranasal products. The figures provide a snapshot of profitability under both standard accounting measures and adjusted metrics that exclude certain items. These quarterly outcomes highlight the company’s financial position and operational results for the period, offering investors a view of revenue generation and earnings performance during the first quarter of fiscal 2026.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is a biopharmaceutical company that develops and markets generic and proprietary injectable, inhalation, and intranasal products. It focuses on complex, hard-to-make medications used in hospitals and clinical settings.

On May 26, mission-critical systems maker for the ******* e and defense sector, Applied Aerospace & Defense, Inc., launched a roadshow for its proposed initial public offering (IPO) of its common stock at an IPO price between $18 and $21 per share, under the ticker symbol “AADX.” The company is set to list 32.50 million shares of its common stock. Bankers plan to price the approximately $633.8 million IPO on June 2, with trading on the New York Stock Exchange on June 3.
We take a closer look at the company now…
Dear Microsoft Stock Fans, Mark Your Calendars for June 2
Microsoft Stock Is Up Nearly 30% From Its March Lows, But You Shouldn’t Sell MSFT Just Yet
Dell Stock Could Be Worth 30% More - Based on Strong AI Demand and FCF

What happened: Broadcom (AVGO) stock edged higher to touch a new intraday all-time high on Wednesday ahead of the chipmaker’s fiscal second quarter results due after the closing bell.
By the numbers: Wall Street **** ysts expect the company to post adjusted earnings of $2.39 per share on revenue of $22.13 billion. The company reported earnings per share of $1.58 per share on revenue of $15 billion for the same three-month period a year ago.
Broadcom is expected to benefit from hyperscaler artificial intelligence spending this year, which is estimated to reach $650 billion. The custom chipmaker’s customers include Google (GOOG, GOOGL), Meta (META), and AI developers Anthropic (ANTH.PVT) and OpenAI (OPAI.PVT).
“Broadcom is priced for perfection going into today, and the bull case is that it might actually deliver perfection,” Mark Malek, chief investment officer at Siebert Financial, wrote in a note on Wednesday.
“The growth has been enormous, they've beaten their own guidance seven quarters running, and the backlog gives them real visibility,” he added.

Some offers on this page are from advertisers who pay us, which may affect which products we write about, but not our recommendations. See our Advertiser Disclosure.
When interest rates for home equity loans and lines of credit are at or near their 2026 lows, like they are right now, it doesn’t mean rate shopping is any less important or impactful. Every lender has its own methodology for pricing home equity loans and HELOCs, so comparison shopping will always be worthy of your time. Your finalized rate will depend on your credit score, the amount of debt you have, and the amount of your loan or line of credit relative to your home's worth.
Learn more: Discover how much you can borrow with a HELOC
Today's national average monthly HELOC adjustable rate is 7.21%. The average fixed rate on a home equity loan is 7.36%, according to data **** ytics company Curinos. Both rates are based on applicants with a minimum credit score of 780 and a maximum combined loan-to-value ratio (CLTV) of 70%.
Learn more: How to choose: HELOC or home equity loan?

DMG Blockchain (TSXV: $DMGI) is moving another part of its bitcoin (CRYPTO: $BTC) mining footprint toward AI infrastructure, signing a letter of intent to provide 50 megawatts of critical IT load to a single AI data center colocation tenant at its Christina Lake facility in British Columbia.
The tenant has not been named and remains under a non-disclosure agreement. DMG said the customer is expected to provide an investment-grade backstop for review as the two sides work toward a definitive agreement. However, the company cautioned that there is no ***** urance a final deal will be reached.
The proposed structure points to a longer-term conversion of the site if the agreement moves forward. The initial term would run for 12 years, with renewal rights for up to three additional five-year periods. DMG plans to deliver the colocation capacity in phases, with the first phase targeted by Dec. 31, 2026.
More From Cryptoprowl:
Ripple, The Company Behind XRP, Is Valued At $50 Billion

Strategy (MSTR) shares fell to $135 after the company sold 32 Bitcoin (BTC) for $2.5M, representing less than 0.004% of its 843,706 BTC holdings.
Coinbase (COIN) stock dropped to $172 as the company’s Q1 net loss of $1.49 per share and 31% YoY revenue decline amplified sensitivity to Bitcoin weakness.
The ***** yst who called NVIDIA in 2010 just named his top 10 stocks and Coinbase wasn't one of them. Get them here FREE.
Shares of Strategy (NASDAQ:MSTR) are down 10% in mid-morning trading Tuesday, while Coinbase (NASDAQ:COIN) stock is off 6%. The catalyst is the tape under both names: Bitcoin (CRYPTO:BTC) has broken below $70,000.
Strategy stock is trading around $135 after a Monday close of $149.78. Coinbase stock is changing hands near $172 versus Monday's $182.61 close. Bitcoin last printed at approximately $67,200, down 5% over the past 24 hours.

The S&P 500 is near record highs. Micron just became a $1 trillion company in 48 trading days.
Credit spreads are historically tight. Jamie Dimon has seen this before.
The JPMorgan Chase CEO has spent the better part of 2026 watching markets climb through the same risks he has been flagging for months. At the Reagan National Economic Forum on May 29, he chose his words carefully.
He did not call it a bubble. He did not tell investors to sell. What he said was more nuanced than either of those things, and more important.
His message deserves to be read in full rather than reduced to its most quotable line.

With an annual dividend yield of 6.30%, Cal-Maine Foods, Inc. (NASDAQ:CALM) is included among the Top 10 High Dividend Stocks to Invest In According to **** ysts.
On May 12, Cal-Maine Foods, Inc. (NASDAQ:CALM) and Sara Lee Frozen Bakery, LLC, a leading manufacturer of premium frozen baked goods, announced that Cal-Maine Foods had acquired certain **** ets of the Van’s Foods business from Sara Lee Frozen Bakery, LLC, a Kohlberg portfolio company.
Van’s is the leading brand in gluten-free waffles and has established itself as a category leader in the rapidly growing better-for-you frozen breakfast market. The acquisition supports Cal-Maine Foods’ strategy to diversify its business, expand its prepared foods business-to-consumer (B2C) retail operations, and create greater value across the supply chain.
The addition of Van’s is expected to increase Cal-Maine Foods’ annual prepared foods sales by about 10% and boost volume by approximately 6% on a pro forma basis. The brand is expected to strengthen the company’s ability to meet changing consumer preferences while expanding its reach across grocery stores, e-commerce platforms, and other direct-to-consumer channels.
Van’s competes in the fast-growing better-for-you frozen breakfast category through broad retail distribution and a strong value proposition centered on taste, convenience, and products designed to meet a variety of dietary needs and preferences.